103 results on '"Haddad, R.I."'
Search Results
2. Pembrolizumab with or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 Study
3. FIERCE-HN: A Multicenter, Randomized, Placebo-controlled, Phase 3 Study of ficlatuzumab + cetuximab in pts w/ recurrent or Metastatic (R/M) HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC)
4. Pre- and Post-treatment Serum Cytokine Expression Signatures and Survival Outcomes in Patients with Head and Neck Squamous Cell Cancer on Anti-PD-1 Therapy
5. A Phase 2 Clinical Trial of Pembrolizumab with Radiation Following Progression on anti-PD-1 Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
6. Zanzalintinib Plus Pembrolizumab Versus Pembrolizumab Alone In Patients with PD-L1 Positive Metastatic Head And Neck Squamous Cell Carcinoma (STELLAR-305): A Double-Blind, Randomized, Placebo-Controlled, Phase 2/3 Study
7. Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma
8. Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer
9. Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions
10. Automated Sarcopenia Assessment and Outcomes in Head and Neck Cancer with Deep Learning Analysis of Cervical Neck Skeletal Muscle
11. Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer
12. The role of oral hygiene in head and neck cancer: results from International Head and Neck Cancer Epidemiology (INHANCE) consortium
13. Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial
14. Screening for Extranodal Extension with Deep Learning: Evaluation in ECOG-ACRIN E3311, a Randomized De-Escalation Trial for HPV-Associated Oropharyngeal Carcinoma
15. Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy
16. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial
17. A Phase 2/3, Randomized, Open-Label Study of Bempegaldesleukin Plus Pembrolizumab vs. Pembrolizumab Alone in First-Line Treatment of Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma with PD-L1-Expressing Tumors (PROPEL-36)
18. Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck
19. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation
20. Deep Learning and Harmonization of Multi-Institutional Data for Automated Gross Tumor and Nodal Segmentation for Oropharyngeal Cancer
21. Oligometastatic Adenoid Cystic Carcinoma: Correlating Tumor Burden and Time to Treatment With Outcomes
22. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
23. Association between Radiation Dose to Organs At risk and Patient Reported Outcome During Treatment for Head and Neck Cancers
24. Chemotherapy outcomes following immunotherapy failure in advanced squamous cell carcinoma of the head and neck
25. Neoadjuvant Nivolumab +/- Ipilimumab in Patients with Oral Cavity Cancer
26. PIK-ing out an intermediate-risk subgroup in advanced adenoid cystic carcinoma
27. Patient Reported Nausea Associated with Concurrent Weekly Versus Bolus Cisplatin in Patients Treated for Head and Neck Cancer
28. Survey of the Adoption of the UICC/AJCC 8th Edition TNM for Head and Neck Cancer: The User’s Initial Experience
29. Local Control following Combination Hypofractionated Radiotherapy and Pembrolizumab in A Phase II Trial of Recurrent or Metastatic Adenoid Cystic Carcinoma Patients
30. Predicting PD-L1 Expression using Radiomics in Oropharyngeal Cancer Patients Treated with Definitive Radiation
31. Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups
32. Final Safety Results of a Phase 1 Clinical Trial of Afatinib in Combination With Docetaxel and Postoperative Radiation Therapy for High-Risk Squamous Cell Carcinoma of the Head and Neck
33. The Current Portfolio of Head and Neck Cancer Trials on ClinicalTrials.gov
34. Somatic Frameshift Alterations in Tumor Suppressor Genes May Predict Anti-PD-1/L1 Response in Squamous Cell Carcinoma of the Head and Neck
35. Outcomes and Patterns of Failure After Postoperative or Definitive Intensity-modulated Radiation Therapy for Oral Cavity Squamous Cell Carcinoma
36. Safety Results of a Multi-Institutional Phase 1 Clinical Trial of Afatinib in Combination with Docetaxel and Postoperative Radiation Therapy for High-Risk Squamous Cell Carcinoma of the Head and Neck
37. Patient Immunosuppression and the Association With Cancer-Specific Outcomes After Treatment of Squamous Cell Carcinoma of the Oropharynx
38. Induction Chemotherapy Followed by Concurrent Chemoradiation Therapy Versus Concurrent Chemoradiation Therapy Upfront in Locally Advanced Oral Cavity Cancer: Systematic Review and Meta-Analysis of Individual Data
39. Variability in Outcome Based on Type of Concurrent Chemotherapy for Treatment of Squamous Cell Carcinoma of the Oropharynx
40. Tumor Biomarker Association With Clinical Outcomes in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Patients (Pts) Treated With Afatinib Versus Methotrexate (MTX): LUX-Head & Neck 1 (LHN1)
41. Systemic Immunologic Effects of Definitive Radiation in Head and Neck Cancer
42. 314O_PR Second-line afatinib vs methotrexate (MTX) in patients (pts) with recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC): subgroup/biomarker analysis of LUX-head and neck 1 (LUX-H&N1)
43. Patterns of Failure After Reirradiation (reRT) With Intensity Modulated Radiation Therapy (IMRT): Not Just a Local Issue
44. Afatinib Versus Methotrexate (Mtx) As Second-Line Treatment for Patients with Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (Hnscc) Who Progressed After Platinum-Based Therapy: Primary Efficacy Results of Lux-Head & Neck 1, a Phase III Trial
45. Toxicity and Survival After Reirradiation (reRT) With IMRT for Recurrent Squamous Cell Cancer of the Head and Neck (SCCHN)
46. Salivary Gland Tumors Treated with Adjuvant Intensity Modulated Radiation with or without Concurrent Chemotherapy: A Recent Experience
47. 8502 Long term (Five-year) results of Tax324: A Phase III Trial of Sequential Therapy comparing TPF with PF in Patients with locally advanced squamous cell cancer of the head and neck
48. Dose to the Larynx Predicts for Swallowing Complications Following IMRT and Chemotherapy
49. 2377
50. 2378
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.